Recent Updates
Recently added Catalysts
PCRX Negative Sentiment Score: 30/100

PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX

Key Takeaway: ClaimsFiler has alerted investors of Pacira BioSciences, Inc. regarding a class action lawsuit for failing to disclose crucial information during the specified Class Period. Investors who purchased securities between August 2, 2023 and August 8, 2024 may file lead plaintiff applications by March 14, 2025. The lawsuit follows a significant share price drop after a court ruled the company's patent on Exparel invalid, impacting around 80% of its revenue. Legal actions are ongoing in the U.S. District Court for the District of New Jersey.

Market Sentiment Analysis

CONCERNS & RISKS

  • Pacira BioSciences is facing a class action lawsuit due to alleged failure to disclose material information.
  • The company's patent for Exparel was deemed invalid, resulting in a significant drop in share price.
  • The lawsuit stems from substantial losses investors could incur due to these disclosures.

Full Press Release Details

NEW ORLEANS, Feb. 27, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the “Company”) (NasdaqGS: PCRX), if they purchased the Company’s securities between August 2, 2023 and August 8, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Pacira investors should visit us at https://claimsfiler.com/cases/nasdaq-pcrx-1/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Pacira and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 9, 2024, the Company released the results of its lawsuit against eVenus for patent infringement relating to its Exparel product, which accounts for approximately 80% of the Company’s revenue, disclosing that the U.S. District Court for the District of New Jersey had “found that the company’s U.S. Patent No. 11,033,495 is not valid,” and, thus, eVenus was not infringing on anything. On this news, the price of Pacira’s shares fell over 47%, from a closing price of $22.36 per share on August 8, 2024 to a low of $11.70 per share on August 9, 2024.
The case is Alvarez v. Pacira BioSciences, Inc., et al., No. 25-cv-00322.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Frequently Asked Questions

What is the deadline to file a lead plaintiff application?

The deadline to file a lead plaintiff application is March 14, 2025.

What is the class period for the Pacira lawsuit?

The class period for the Pacira lawsuit is from August 2, 2023, to August 8, 2024.

How much did Pacira's shares drop after the lawsuit announcement?

Pacira's shares dropped over 47% after the lawsuit announcement.

Who can Investors contact for legal options regarding Pacira?

Investors can contact Kahn Swick & Foti, LLC for discussions on legal options.

What does ClaimsFiler offer to investors?

ClaimsFiler offers free registration for access to securities class action settlements.

Last updated: Feb 27, 2025